A comprehensive new analysis published in Frontiers in Medicine—“Harmonizing Health: A Global Analysis of Pharmaceutical Regulatory Activities by International Regulatory Organizations” (Dangy-Caye et al., 2025)—offers critical insight into how international bodies are shaping the future of medicines regulation. The report, which examined over 3,000 projects from six leading organizations (ICH, WHO, PIC/S, IPRP, ICMRA, and IMDRF), highlights how coordinated regulatory action is supporting faster access to high-quality, safe, and effective medicines worldwide.

At the GMDP Academy, our mission is to become the global hub for education and training in the field of medicines development. This study underscores the importance of global cooperation and capacity-building—two values that are at the core of our educational model. By fostering patient-centered scientific knowledge and advancing professional standards in pharmaceutical medicine, we are preparing the workforce needed to support a more harmonized, collaborative regulatory environment.

Convergence, Quality, and Public Health: Where the Global Focus Lies

The study categorized regulatory activities into 10 topic domains. The four most active areas were:

  • Quality (24.4%)
  • Public Health (19.9%)
  • Convergence and Reliance (14.2%)
  • Pharmacovigilance (9.5%)

These priorities align with the GMDP Academy’s Certification in Medicines Development (CMD) curriculum, offered in collaboration with King’s College London. Modules include:

To address emerging needs in digital innovation, the Academy also offers Module 8: Digital Technology in Medicines Development, focusing on AI, real-world evidence, and the evolving regulatory landscape.

The Rise of Reliance Pathways and Global Participation

The study highlights how regulatory reliance—where national authorities build on trusted foreign regulatory assessments—is accelerating global medicine access. Countries actively participating in international organizations were found to use reliance routes more frequently.

Key examples include:

  • China, which reduced submission lag by 622 days after joining ICH.
  • Brazil, Indonesia, and Taiwan (referred to as Chinese Taipei in international regulatory contexts), all showing marked improvements.
  • Singapore, which submitted over 72% of new active substances through reliance-based pathways during 2021–2022.

Such outcomes reflect both the operational efficiency and public health value of harmonized regulatory practices.

Global Membership and the Role of Education

The study also found that ICH member countries are significantly more engaged across all five other global regulatory bodies. Over one-third of ICH members hold full cross-membership, while none of the 185 non-ICH members participate in all six organizations. This underscores how global regulatory leadership is closely linked to education, infrastructure, and professional development.

At the GMDP Academy, our ten-month CMD program provides a rigorous foundation in pharmaceutical medicine. With modules spanning clinical science, ethics, pharmacovigilance, and regulatory strategy, we support both individual career growth and institutional capacity building.

Conclusion: Advancing Medicines Development as a Global Profession

This global analysis affirms that regulatory harmonization is both a strategic imperative and a professional challenge. While frameworks and guidelines form the backbone, it is the trained professionals—scientists, regulators, and medical affairs leaders—who make convergence possible.

As the pharmaceutical landscape becomes more interdisciplinary and globally interconnected, the GMDP Academy remains committed to developing the next generation of experts who will lead with purpose, adaptability, and scientific integrity.

Join the Movement Toward Global Regulatory Excellence

As regulatory science becomes more collaborative and internationalized, the need for well-trained, globally minded professionals has never been greater. Whether you’re advancing your career, building regulatory capacity within your organization, or shaping the future of medicines development policy—GMDP Academy offers the knowledge, credentials, and global perspective to help you lead.

🔹 Explore our Certification in Medicines Development (CMD)
 🔹 Enroll in specialized modules, including digital innovation and regulatory strategy
🔹 Join a growing network of professionals committed to ethical, patient-centered global health

Visit gmdpacademy.org to learn more—or contact us at admissions@gmdpacademy.org to start your journey.

Reference

Dangy-Caye, A., Mousset, A., Kermad, A., Bouché-Bazerolle, L., Bujar, M., De Lucia, M.-L., McAuslane, N., & Lumsden, R. (2025). Harmonizing health: A global analysis of pharmaceutical regulatory activities by international regulatory organizations. Frontiers in Medicine, 12, 1636269. https://doi.org/10.3389/fmed.2025.1636269

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred